Summit Therapeutics (SMMT) Cash from Operations (2019 - 2026)

Summit Therapeutics has reported Cash from Operations for 8 years, with the latest figure at 122291000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 99.93% year-over-year to 122291000.0; the trailing twelve-month figure through Mar 2026 stood at 384053000.0 (down 121.82% YoY), and the FY2025 full-year result was 322930000.0, down 127.25% from the prior year.
• Cash from Operations for Q1 2026 stood at 122291000.0, down from 101938000.0 in the prior quarter.
• The five-year high for Cash from Operations was 5191000.0 in Q4 2022, with the low at 122291000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 41509941.18 across 5 years, with a median of 30134000.0 in 2024.
• Annual changes were most pronounced in 2022 — Cash from Operations surged 156.55% — and 2023, when it plunged 474.86%.
• Summit Therapeutics' Cash from Operations stood at 5191000.0 in 2022, then sank by 474.86% to 19459000.0 in 2023, then tumbled by 150.13% to 48673000.0 in 2024, then tumbled by 109.43% to 101938000.0 in 2025, then dropped by 19.97% to 122291000.0 in 2026.
• The last three Cash from Operations figures came in at 122291000.0 (Q1 2026), 101938000.0 (Q4 2025), and 93080000.0 (Q3 2025), per Business Quant data.